We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A small biotech that has been working on developing one treatment for the last decade has finally seen the fruits of their labour, with Mundipharma swooping to take CAP7.I into Phase 3 trials.